HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmair

This article was originally published in The Rose Sheet

Executive Summary

Lancome Vitalite Douceur body care collection comprises three new products -- Douceur Pure Cleansing Body Milk, Gommage Pur Exfoliating Body Gel and Energibuste Firming-Toning Bust Treatment; two reformulated and repackaged products -- Savon Fraichelle Invigorating Body Cleansing Gel and Exfoliant Fraichelle invigorating Body Scrub; and two existing products -- Stimulative Dual Action Body Creme and Hydra-Balance Essential Hydrating Body Lotion. All of the items contain magnesium, which combats free radicals; essential fatty acids, said to "contribute to a sort, supple and radiant skin"; and provitamin B[5], which encourages moisture recovery, according to the firm. The new and existing items will be presented together under the Vitalite Douceur name beginning in April. Suggested retail prices for the products range from $20 for a 6.8 oz. tube of Savon Fraichelle to a 6.8 oz. jar of Stimulative Dual Action Body Creme

You may also be interested in...



UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel